US FDA confirms biosimilars regulation meeting dates
This article was originally published in SRA
The US Food and Drug Administration has formally announced that it will hold a two-day public hearing to gather feedback from stakeholders on specific issues and challenges associated with the implementation of the Biologics Price Competition and Innovation Act of 20091-3.
You may also be interested in...
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.
The EU product information for Ibrance, Verzenios and Kisqali is being updated to include interstitial lung disease and pneumonitis. The change has already been implemented in the US.